{
  "run_id": "9857c7ed-d3fb-4a28-ade2-2eddc1bf1cdf",
  "prompt_variant_id": "c98d33e9-6675-4b9e-8610-8ac216763bf3",
  "api_config_name": "model_deepseek_chat",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-08-30T22:47:23.945237",
  "end_time": "2025-08-30T22:53:16.009610",
  "duration_ms": 352060.4290962219,
  "success": true,
  "error_message": "",
  "entities_extracted": 25,
  "entities_mapped": 25,
  "extraction_completeness": 1.5625,
  "mapping_accuracy": 0.5,
  "precision": 0.5555555555555556,
  "recall": 0.9375,
  "f1_score": 0.6976744186046512,
  "compliance_score": 1.0,
  "token_usage": 6235,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 25,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Histologically confirmed HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "30-80",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "55-68",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "82-112",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "102-112",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "114-140",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "142-164",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "180-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "200-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "222-244",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "246-268",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": "20-40",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": "60-73",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": "74-95",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.8,
      "source_context": {
        "section": "briefSummary",
        "position": "100-110",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": "120-145",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-45",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-65",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-33",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "30-43",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "10-18",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": "15-28",
        "context_sentence": "briefTitle: Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": "20-42",
        "context_sentence": "officialTitle: A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct mapping to cancer condition with HER2 biomarker status",
      "id": "c40040db-b644-4e88-88fc-40191d298d25",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "8ee59768-d641-4df1-b6f1-716662ec747f",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "1649fcca-4a46-4f03-9eeb-019160ddb831",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "b258f508-5f23-450c-b99f-37d58d69fe5f",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "67daf9c5-429e-4b72-9bcd-e6de8acfeaf4",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "active",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Measurable disease indicates active cancer status",
      "id": "2362db6f-ef6c-4389-99f8-aa07e61b059a",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "RECIST criteria used for cancer response assessment procedure",
      "id": "bc24e1ea-f4e1-4f35-9410-36ee47724b39",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Direct mapping to ECOG performance status score",
      "id": "17d4aee2-94aa-4bb4-a352-b36a3acbde5e",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "adequate organ function",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "General condition related to cancer treatment eligibility",
      "id": "26ee0b2c-f5ea-4376-b281-70550d34f7c1",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Cancer medication with negative status indicating exclusion",
      "id": "f0346034-19ee-4701-bb3a-2482508307aa",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Direct mapping to cancer-related medication",
      "id": "5da3f6fc-3c3b-442a-938d-d19c0f31d898",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Metastatic cancer condition with negative status indicating exclusion",
      "id": "cf973198-2c72-4072-b608-025578052441",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "pregnancy or breastfeeding",
      "mapping_confidence": 0.6,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "General medical condition affecting cancer treatment eligibility",
      "id": "1c24c97b-3643-4119-86c6-c8bdc833155b",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "General category of cancer-related medication",
      "id": "6d4e3a65-5e2b-461c-a5dd-8c0af172e2ce",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "ed9ec58e-b9ac-43df-ad41-08b75fa80242",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "e95c745b-4d7a-425b-bc48-9eee2e3fed41",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "progression",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Disease progression status indicating cancer disease state",
      "id": "3ad8b65b-91db-4237-9be1-587e238d2c08",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Cancer medication category with past temporal context",
      "id": "9dac26e4-da23-48b7-9fb0-e5e1332490cb",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 18",
      "mapping_rationale": "Direct mapping to cancer condition with biomarker",
      "id": "3d7b25ba-4dad-49b6-8871-949a2204e1e0",
      "llm_source_text_fragment": "Entity index 18",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 19",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "6c22db29-3486-4957-8c83-e01dad188ca0",
      "llm_source_text_fragment": "Entity index 19",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 20",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "de462fac-69a3-49ee-a690-621997f751da",
      "llm_source_text_fragment": "Entity index 20",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 21",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant",
      "id": "627d2666-ef03-43db-900f-fe400e8ed6e5",
      "llm_source_text_fragment": "Entity index 21",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "Phase III clinical trial",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 22",
      "mapping_rationale": "Clinical trial phase as cancer-related procedure",
      "id": "b102332f-7fd1-450c-b649-16a9daf2ccf2",
      "llm_source_text_fragment": "Entity index 22",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 23",
      "mapping_rationale": "Investigational cancer medication with future context",
      "id": "8b54c40f-ed8e-49ab-bc53-50f40d01654c",
      "llm_source_text_fragment": "Entity index 23",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 24",
      "mapping_rationale": "Investigational cancer medication with future context",
      "id": "9561d042-94c0-47b3-bdf3-3c7658ac7aea",
      "llm_source_text_fragment": "Entity index 24",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}